Brief: Arctic Bioscience: Encouraging Top-Line Results From The Heropa Clinical Study
April 24 (Reuters) - Arctic Bioscience AS ABSA.OL: ARCTIC BIOSCIENCE ANNOUNCES ENCOURAGING TOP-LINE RESULTS FROM THE HEROPA CLINICAL STUDY HRO350 WELL TOLERATED WITH NO NEW SAFETY CONCERNS Source text: ID:nWkr9ZyWhf Further company coverage: ABSA.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Arctic Bioscience AS
See all newsNorway's Arctic Bioscience Q1 sales rise 78% to record on America boost
Brief: Arctic Bioscience Q1 Adjusted EBITDA NOK -6.5 Million
Norway's Arctic Bioscience 2025 revenue falls due to product recall impact
Brief: Arctic Bioscience Q3 Adjusted EBITDA NOK -7.8 Million
Brief: Arctic Bioscience H1 Adjusted EBITDA NOK -13.6 Million